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Dexamethasone-treated WEHI7.2 mouse thymoma cells readily undergo apoptosis. WEHI7.2 variants that overexpress catalase (CAT38)
or Bcl-2 (Hb12) show a delay or lack of apoptosis, respectively, when treated with dexamethasone. This is accompanied by a delay or lack of
cytochrome c release from the mitochondria suggesting that alterations in the signaling phase of apoptosis are responsible for the observed
resistance. Because membranes are a rich source of signaling molecules, we have used 31P NMR spectroscopy to compare phospholipids and
their metabolites in WEHI7.2, CAT38 and Hb12 cells after dexamethasone treatment. Increased lysophosphatidylcholine (lysoPtdC) content
accompanied phosphatidylserine (PtdS) externalization in the WEHI7.2 cells. Both changes were delayed in CAT38 cells suggesting
phosphatidylcholine (PtdC) metabolites may play a role in steroid-induced apoptotic signaling. The steroid-resistant Hb12 cells showed a
dramatic increase in glycerophosphocholine (GPC) content, suggesting increased phospholipid turnover may contribute to the anti-apoptotic
mechanism of Bcl-2.
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Glucocorticoid-induced apoptosis in lymphocytes is a
well-documented process that is important physiologically
for the sorting of immature lymphocytes and has been
exploited clinically for the treatment of leukemia and
lymphoma [1]. Resistance either initially or developed
during the course of treatment can limit the use of
glucocorticoids as chemotherapeutic agents and, in acute
lymphoblastic leukemia, is correlated with poorer progno-
sis [2]. A decrease in or lack of functional glucocorticoid
receptors has been shown to cause resistance in cell
culture and in the clinic [3–5]; however, only a portion
of the resistance can be attributed to receptor alterations
[6–9]. Elucidating the events that occur during the sig-
naling phase of glucocorticoid-induced apoptosis, i.e. after
the translocation of the steroid-receptor complex to the
nucleus and prior to the release of cytochrome c into the
cytosol, is key to understanding steroid resistance and
developing chemotherapeutic agents that circumvent this
resistance.
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asone, a synthetic glucocorticoid, readily undergo apoptosis.
Enhancing the endogenous antioxidant defense in WEHI7.2
cells through overexpression of catalase or thioredoxin or
selection for resistance to hydrogen peroxide results in
WEHI7.2 variants that are protected from steroid-induced
apoptosis [10–12]. The degree of protection is correlated
with a delay or lack of cytochrome c release into the cytosol.
Overexpression of Bcl-2, a protein which protects against
apoptosis by reactive oxygen species (ROS) [13–16] and
has been shown to alter the redox status in some cell types
[17], also protects against glucocorticoid-induced apoptosis
in WEHI7.2 cells [18]. Taken together, these data suggest
that signaling pathways sensitive to ROS or the products of
ROS-induced damage may be critical to steroid-induced
apoptosis.
Membranes are a rich source of signaling molecules and
a major target of ROS. There is some evidence that lipid
peroxidation occurs after steroid treatment of lymphocytes
[13,19]. Further, treatment of WEHI7.2 cells with a vitamin
E analog protects the cells from steroid-induced apoptosis
[20]. A direct attack by ROS on membranes can result in the
release of lipid peroxidation products that damage proteins
and DNA and alter membrane phospholipid composition
[21]. Perturbations in membrane phospholipid composition
may be important for both phospholipid and membrane-
bound protein signaling molecules [22]. Dexamethasone
treatment alters membrane fluidity in some systems
[23,24] and has been shown to suppress phospholipid
synthesis [25,26] suggesting that steroid treatment may
affect membrane phospholipid composition. Alternatively,
oxidative stress has been shown to stimulate production of
ceramide [27], a sphingolipid metabolite that is a well-
documented apoptotic signal [28]. Steroids have been
reported to stimulate ceramide generation in thymocytes
as part of the apoptotic cascade [29].
The goal of this study was to identify alterations in
phospholipids or phospholipid metabolites due to dexameth-
asone treatment that differ depending on the steroid sensi-
tivity of the WEHI7.2 variants. To generate a global picture
of phospholipid perturbations, we have used 31P NMR
spectroscopy because this method allows us to examine a
large number of phospholipids and their metabolites in one
sample. We have focused on steroid-induced phospholipid
changes in three WEHI7.2 variants with different steroid
sensitivities: (1) WEHI7.2 cells, the parental steroid-sensi-
tive cells; (2) CAT38 cells, WEHI7.2 cells expressing 1.4-
fold parental cell catalase activity, that show delayed apo-
ptosis after dexamethasone treatment [11]; and (3) Hb12
cells, WEHI7.2 cells overexpressing Bcl-2 [18], that show
no markers of apoptosis after a 48-h steroid treatment.
Measurement of alterations over time after dexamethasone
treatment has also allowed us to identify pathways poten-
tially involved in signaling during steroid-induced apoptosis
in these cells. Portions of this work have been published in
abstract form [30].2. Materials and methods
2.1. Cell culture and drug treatment
WEHI7.2 mouse thymoma cells [31] were obtained from
Dr. Roger Miesfeld (University of Arizona, Tucson, AZ).
Cells were cultured in Dulbecco’s Modified Eagle Medium-
low glucose (GIBCO-BRL Products, Grand Island, NY)
supplemented with 10% calf serum (Hyclone Laboratories,
Logan, UT) at 37 jC in a 5% CO2 humidified environment.
These cells were maintained in exponential growth at a
density between 0.02 and 2 106 cells/ml. WEHI7.2 cells
stably transfected with and overexpressing human Bcl-2
(Hb12), also obtained from Dr. Miesfeld, were constructed
and maintained as described by Lam et al. [32]. Catalase-
overexpressing WEHI7.2 cells (CAT38) were constructed
and cultured in the presence of 800 Ag/ml G418 (GIBCO-
BRL) to ensure continued catalase expression as described
in Tome et al. [11]. CAT38 cells were subcultured in the
absence of selection drug for 1 week prior to sampling.
Immediately before each experiment, live cells were sepa-
rated from those that underwent spontaneous apoptosis
using Ficoll-Plaque Plus reagents and the manufacturer’s
suggested protocol (Amersham Pharmacia Biotech, Piscat-
away, NJ). Cells were subcultured into medium and incu-
bated in the presence of 1 AM dexamethasone (Sigma
Chemical Co., St. Louis, MO) or ethanol as a vehicle
control (final conc. = 0.01%) for indicated times before
harvest.
2.2. Annexin binding and cell cycle analysis
Cells were harvested by centrifugation (500 g for 5
min) and washed twice with PBS. For % apoptosis, the cells
were incubated with annexin V and propidium iodide
according to the manufacturer’s instructions (Apoptosis
Detection Kit, R&D Systems, Minneapolis, MN). Cells that
were annexin V-positive and propidium iodide-negative
were scored as apoptotic. For cell cycle analysis, the cells
were resuspended in Krishan’s Buffer (0.1% sodium citrate;
0.02 mg/ml RNase; 0.3% IGEPAL; 50 Ag/ml propidium
iodide) and incubated overnight at 4 jC. Both types of
samples were analyzed using a FACScan flow cytometer
with CellQuest software (Becton Dickinson, San Jose, CA).
Ten thousand cells were analyzed per sample. Samples from
exponentially growing untreated cell cultures 24 h after
subculture were used as control samples.
2.3. 31P NMR spectroscopy
Approximately, 6–8 108 cells from cultures at a
density of 7–8 105 cells/ml were harvested for each time
point. NMR samples were prepared, NMR data acquired
and data processed as described by Lutz et al. [33]. Briefly,
cells were harvested by centrifugation, washed and fixed
by adding methanol. Chloroform and water were added to
Fig. 1. Apoptosis and G1 accumulation in the WEHI7.2 (.) cell culture
compared to CAT38 (n) and Hb12 (x) cell cultures after the addition of
dexamethasone (time = 0). (A) Each symbol represents the mean percentage
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 20 jC overnight and subsequent centrifugation. Solvents
were evaporated from the aqueous and organic phase
samples and the aqueous phase lyophilized. Samples were
stored at  80 jC until analysis. The lipid sample was
dissolved in a 2H-chloroform–methanol–water solution
containing 1,2-diamine-tetraacetic acid and the lyophilizate
was dissolved in a D2O solution containing 50 mM 1,2-
diamine-tetraacetic acid. 31P NMR spectra were obtained at
202.5 MHz on a vertical, narrow-bore 11.7T Bruker
Avance DRX 500 FT NMR spectrometer (Bruker, Rhein-
stetten, Germany) using a broadband probe for 5 mm
tubes. Signals were assigned as described previously
[33], except for glycerophosphoglycerol (GPG). GPG and
bis(glycerol 3-phospho)glycerol (GPGPG), which have
similar chemical shifts, were obtained by saponification
of phosphatidylglycerol and cardiolipin, respectively [34].
Spiking the sample with GPG or GPGPG resulted in the
exact superimposition of the GPG signal on the unidenti-
fied phosphodiester (PDE) region peak. Total sample
protein was measured by using the BCA Protein Assay
Kit (Pierce Chemical Company, Rockford, IL) as described
in Ref. [33]. Metabolite concentrations were expressed as
nmol/mg cellular protein.
2.4. Statistics
Fisher’s protected least significant difference test for
multiple comparisons, a type of ANOVA, was used to test
for significant differences between samples (StatView, SAS
Institute, Cary NC). Samples were considered significantly
different if PV 0.05. Values reported are meanF S.E. (n = 3
or 4). The difference in % apoptosis was calculated by (%
apoptosis +DEX) (% apoptosisDEX); then this differ-
ence was correlated to [(phospholipid +DEX) (phospho-
ospholipidDEX)]. Regression analyses, using the
algorithm in Excel (Microsoft Corporation, Redmond,
WA), were used to calculate correlation coefficients (r).
of the cells that are annexin V positive and propidium iodide
negativeF S.E. (n= 3). Where error bars are not visible, they are contained
within the symbol. This is a representative experiment which has been
replicated. (*) denotes significantly greater than control values (C) for the
same cell variant ( PV 0.05). (B) Each symbol represents the mean
percentage of cells in G1F S.E. (n= 3). (*) Denotes significantly greater
than cells cultured in the absence of dexamethasone for the same time
( PV 0.05).3. Results
3.1. Phosphatidylserine (PtdS) exposure (% apoptosis) and
cell cycle analysis
Exposure of PtdS on the external surface of the plasma
membrane has been used as a marker of apoptosis [35]. Fig.
1A shows a comparison of PtdS exposure in WEHI7.2,
CAT38 and Hb12 cells as a measure of apoptosis after
dexamethasone treatment. This information provides a
reference point for the other phospholipid changes de-
scribed in this study. WEHI7.2 cells showed significantly
increased apoptosis by 16-h post-dexamethasone treatment.
The CAT38 cells showed a delayed increase in PtdS
exposure (28 h after dexamethasone treatment), while
Hb12 cells did not show an increase in PtdS exposure overthis time course. In WEHI7.2 cells, we see a small amount
of cytochrome c release into the cytosol by 16-h post-
treatment and substantial release by 24 h [11]. CAT38 cells
do not show increased cytosolic cytochrome c release until
32 h after treatment [11]. Release of cytochrome c occurs
prior to an increase in the number of cells displaying
apoptotic morphology in each variant [11]. Significant
increases in PtdS occurred slightly before or concomitant
with cytochrome c release into the cytosol. This indicates
that increased PtdS exposure preceded or coincided with
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after 24 h in untreated cell cultures (C values) was also
significantly different. The WEHI7.2 cells showed the
greatest percentage of apoptosis, CAT38 an intermediate
amount and Hb12 cells the least.
Glucocorticoid treatment also causes a slowing of the
cell cycle in lymphocytes resulting in the accumulation of
cells in G1 [36]. Fig. 1B shows the effect of dexametha-
sone treatment on G1-phase accumulation. C values are the
relative number of cells in G1 after 24 h in culture in the
absence of dexamethasone for comparison. In the presence
of dexamethasone, WEHI7.2 cells showed little change in
the percentage of cells in G1. CAT38 cells accumulated in
G1 after 40 h in dexamethasone while a significant increase
in the percentage of cells in G1 was already apparent by 12Fig. 2. Characteristic 31P NMR spectra of extracts prepared from WEHI7.2 cells
represents the expanded low-field region of the spectrum to illustrate some of the m
phosphocholine; Pi, inorganic phosphate; NTP, nucleoside triphosphate; Gro-3-P
phoethanolamine; GPG, glycerophosphoglycerol. (B) Phospholipid spectrum f
phosphatidylcholine; (2) 1-alkyl-2-acyl-phosphatidylcholine; (3) phosphatidylinosi
(7) phosphatidylethanolamine; (8) phosphatidylethanolamine plasmalogen; (9) 1-a
glycerol. (C) Phospholipid spectrum from a 24-h dexamethasone-treated sample. Th
these samples.h after the addition of dexamethasone to Hb12 cell
cultures.
3.2. Comparison of phospholipid alterations to apoptosis
and G1
We have used 31P NMR spectroscopy to quantify mul-
tiple phospholipids and their metabolites at several time
points during culture in the presence and absence of
dexamethasone. Fig. 2 shows typical 31P NMR spectra for
both aqueous (A) and organic (B) phases of the sample to
illustrate the metabolites that were quantifiable in these
samples.
As an indication of the importance of each metabolite in
apoptosis, we correlated the change in % apoptosis with. (A) Aqueous-phase spectrum of a 24-h ETOH-treated sample. The inset
etabolites seen at a lower concentration. Abbreviations are as follows: PC,
, glycerol 3-phosphate; GPC, glycerophosphocholine; GPE, glycerophos-
rom a 24-h ETOH-treated sample. Peaks are assigned as follows: (1)
tol; (4) lysophosphatidylcholine; (5) phosphatidylserine; (6) sphingomyelin;
lkyl-2-acyl-phosphatidylethanolamine; (10) cardiolipin; (11) phosphatidyl-
e arrow indicates the alteration in peak height of lysophosphatidylcholine in
Table 1
Correlation of phospholipids and phospholipid metabolites to % apoptosis
and % G1
Lipid CORR (r) Lipid CORR (r)
% Apoptosisa LysoPtdC 0.9189* % G1 PDE 0.8913*
vs.
SM 0.8713*
vs.
GPC 0.8877*
PC  0.7583* GPE 0.8782*
AAPtdEpl 0.7529* PME/APDE  0.6114*
Ptot 0.7468* AAPtdE 0.5674*
AAPtdC 0.7099* PC 0.5014*
PtdC 0.7057* AAPtdEpl 0.5007*
PME/APDE  0.6702* GPG 0.4864*
PdtI 0.6671* Ptot 0.1581
PtdS 0.5900 PtdS  0.1190
GPG  0.4888 SM  0.1028
GPE  0.2396 PdtI  0.0833
PDE  0.2258 AAPtdC 0.0492
AAPtdE  0.2107 PtdC 0.0313
GPC  0.1701 LysoPtdC  0.0331
a The percentage of apoptosis in the absence of drug was subtracted
from the percentage of apoptosis in the presence of drug. This difference
was then correlated to the difference in each phospholipid or metabolite
(phospholipid in the presence of drug minus phospholipid in the absence of
drug).
*Denotes significant correlation ( PV 0.05).
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Table 1. We also compared the percentage of cells in G1
with individual metabolite concentrations. Lysophosphati-
dylcholine (lysoPtdC) showed the greatest positive corre-
lation with % apoptosis and the phosphodiesterase (PDE)
showed the greatest positive correlation with the percent-
age of cells in G1 when all the cell variants and time points
were examined together.
However, an overall analysis can obscure important cell
specific differences. For example, glycerophosphocholine
(GPC) was highly correlated with % G1 in Hb12 cells
(r = 0.9238), but in WEHI7.2 cells it was highly correlated
with % apoptosis (r = 0.8665) and not at all with % G1
(r = 0.5338). The WEHI7.2 cells primarily underwent
apoptosis in response to dexamethasone treatment and
Hb12 cells primarily accumulated in G1. This makes it
possible to separate phospholipid changes into those that
are correlated with apoptosis, those that are correlated with
accumulation in G1 and those that depend on treatment by
examining the variants independently. To determine which
lipid changes correlated with the onset of apoptosis in the
sensitive cells and identify alterations that occur shortly
after the addition of dexamethasone (potentially involved in
apoptosis signaling), it was necessary to examine some of
the metabolites in more detail.
3.3. Choline phospholipids
Although phosphatidylcholine (PtdC), the most abundant
membrane lipid, is maintained at a relatively constant
percentage in cells, the dynamic flux of PtdC cycling (Fig.
3A) is critical for producing other lipids and maintaining
cell viability [37–39]. Perturbations in PtdC synthesis,degradation and remodeling can cause apoptosis in many
cell types (e.g. Refs. [40–46] and others).
Both PtdC and lysoPtdC were altered by dexamethasone
treatment in the steroid-sensitive cells (Figs. 2C and 3B).
LysoPtdC content was significantly increased 12 h after
dexamethasone addition in the steroid-sensitive WEHI7.2
cells and continued to increase out to 32-h post treatment. In
CAT38 cells the increase was delayed, not appearing until
32 h in dexamethasone and continuing to increase out to 40
h, corresponding to the delay in the appearance of apoptotic
markers in these cells. In the steroid-resistant Hb12 cells no
consistent change was observed. In the absence of dexa-
methasone, CAT38 cells showed an increase in lysoPtdC
after 40 h in culture which corresponded to an increase in
spontaneous apoptosis (8.47F 0.12% in control vs.
18.03F 0.69% at 40 h), under these culture conditions.
PtdC (Fig. 3B) also increased significantly after dexameth-
asone treatment in the WEHI7.2 cells and slightly at 40
h after dexamethasone treatment in CAT38 cells when the
cells were undergoing increased apoptosis.
WEHI7.2 cells showed increased GPC, a PtdC degrada-
tion product, in the presence of dexamethasone. CAT38
cells showed an increased GPC in the presence of dexa-
methasone as well, but to a lesser extent. In contrast, Hb12
cells showed a dramatic increase in GPC in the presence of
dexamethasone and a more modest increase in GPC in the
absence of dexamethasone. The GPC concentration in the
Hb12 cells seen after 24 h in the absence of drug was still
greater that the GPC concentration in the WEHI7.2 cells
after 32 h in the presence of dexamethasone.
Dexamethasone treatment also affected glycerol 3-phos-
phate (Gro-3-P) and phosphocholine (PC) independent of
the steroid sensitivity of the cells. Gro-3-P can be a product
of phospholipid degradation, but is also a precursor of
diacylglycerol (DAG) or cardiolipin (CL) biosynthesis and
a glycolytic intermediate. All three cell variants generally
showed a decrease in Gro-3-P in response to dexamethasone
treatment. Phosphocholine (PC), a product of choline kinase
during PtdC synthesis, can also be a by-product of PtdC
hydrolysis by PC-dependent phospholipase C (PLC) or
sphingomyelin (SM) breakdown. Initially, dexamethasone
caused an increase in intracellular PC in all three cell
variants, but by the later time points the levels were similar
to those in control (ETOH) cells. No cytidine diphosphate-
choline (CDP-choline) was detected in these spectra and
quantifiable choline was not seen in the 1H spectra. The
correlation of choline lipid alterations to increased PtdS
exposure suggests that choline lipid metabolites may be
important to the mechanism of steroid-induced lymphocyte
apoptosis.
3.4. Phosphomonoesters (PME) and PDE
The relative amount of PME vs. PDE components in
cells is used as an indicator of the biological status of cells
(see Ref. [37] for review). For example, a relative increase
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proliferation in a number of studies [37]. Relative increases
in PDE have been linked to multiple cellular eventsincluding cell cycle arrest, chemotherapeutic response
[37,46], changes in osmolyte demand [47] and overexpres-
sion of Nm-23 [48]. We have compared individual PME
Fig. 4. Comparison of phosphodiester concentrations in WEHI7.2, CAT38 and Hb12 cells over time in the presence and absence of dexamethasone.
Abbreviations are: PDE, phosphodiester; and as in Fig. 2. Each bar represents the mean + S.E. (n= 3 or 4). (*) Denotes significantly different from the ETOH-
treated sample of the same cell variant at the same timepoint ( PV 0.05).
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assess phospholipid metabolism in response to dexameth-
asone treatment.
The two major PME usually seen in mammalian cells are
PC and phosphoethanolamine (PE). In this study, the only
quantifiable phospholipid PME was PC, which has been
discussed above. Phosphatidylethanolamine (PtdE) can be
synthesized and degraded similar to PtdC [37] and was
present at f 20 nmol/mg prot in the three cell variants in
the presence and absence of dexamethasone, except that the
WEHI7.2 32-h ETOH sample contained significantly less
(16.21F1.4 nmol/mg prot) than the 32-h dexamethasone-
treated sample (21.43F 0.72 nmol/mg prot). PE, the PtdE
metabolite analogous to PC, was not detectable in these
samples.Fig. 3. Comparison of phosphatidylcholine and related metabolites in WEHI7
dexamethasone. (A) Choline lipid metabolism in mammalian cells [37,51]. Abbre
diacylglycerol; PA, phosphatidate; FA, fatty acid; CoA, coenzyme A; P
glycerophosphocholine; Gro-3-P, glycerol 3-phosphate; ck, choline kinase; ct,
transferase; PLA2, phospholipase A2; PLC, phospholipase C; PLD, phospholipase
absence of dexamethasone. Abbreviations are as in Figs. 2 and 3. Each bar rep
significantly different from the ETOH-treated sample of the same cell variant atThree PDE peaks were quantifiable in the samples. In
addition to GPC, the PtdC degradation product discussed
above, glycerophosphoethanolamine (GPE) and GPG, were
seen in these samples (Fig. 4). GPE is the breakdown product
of PtdE, analogous to GPC in PtdC metabolism. GPE
increased in all three cell variants in response to dexameth-
asone treatment. As with GPC, the greatest amount of GPE
was seen in the Hb12 cells, particularly in the presence of
dexamethasone. GPE concentration also increased over time
in the control (ETOH) samples in all three variants, but not to
as great an extent. GPG, a phosphatidylglycerol (PtdG) and
CL breakdown product, was also higher in CAT38 and Hb12
cells, in particular, compared to the WEHI7.2 cells.
The ratio of PC to APDE in the three variants is shown in
Fig. 4 (bottom panel). PC/APDE decreased over time in the.2, CAT38 and Hb12 cells over time in the presence and absence of
viations are as follows: CDP-choline, cytidine diphosphate-choline; DAG,
tdC, phosphatidylcholine; LysoPtdC, lysophosphatidylcholine; GPC,
phosphocholine cytidylyltransferase; CPT, phosphocholine diacylglycerol
D. (B) Choline lipid metabolites and Gro-3-P over time in the presence or
resents the mean metabolite concentration + S.E. (n= 3 or 4). (*) Denotes
the same time point ( PV 0.05).
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sone. However, after 12 h in dexamethasone the value was
significantly lower than in the absence of drug (12-h ETOH)
and continued to drop out to 32 h as the cells were undergoing
apoptosis. CAT38 cells in the control and early dexametha-
sone-treated time points had a ratio similar to WEHI7.2 cells
after 24 h in the absence of drug. The ratio dropped in the 40-
h dexamethasone-treated CAT38 sample as the cells were
undergoing apoptosis and accumulating in G1. Hb12 cells
had a very low PC/APDE ratio compared to the other two cell
variants primarily due to the increased PDE content of these
cells. These data suggest that: (1) PC/APDE drops as the cells
are undergoing apoptosis and/or accumulating in G1, and (2)
increased resistance to steroid-induced apoptosis is correlated
with an increased concentration of PDE.
3.5. Ether-linked phospholipids
Alterations in ether-linked lipid concentrations can alter
susceptibility to ROS and blockage of ether-linked lipid
remodeling can induce apoptosis [40,49,50]. To determine
whether dexamethasone affected the ether-linked lipids, weFig. 5. Comparison of ether-linked lipid concentrations in WEHI7.2, CAT38 a
Abbreviations are: AAPtdC, 1-alkyl-2-acyl-phosphatidylcholine; AAPtdE, 1-alk
plasmalogen. Each bar represents the mean metabolite concentration + S.E. (n= 3 o
same cell variant at the same timepoint ( PV 0.05).examined the alterations in the three ether-linked phos-
pholipids quantifiable in these spectra: 1-alkyl-2-acyl-
phosphatidylcholine (AAPtdC); 1-alkyl-2-acyl-phosphati-
dylethanolamine (AAPtdE); and phosphatidylethanolamine
plasmalogen (PtdEplasm). As shown in Fig. 5, AAPtdC was
significantly increased in the WEHI7.2 cells after 24 h in the
presence of dexamethasone and was further increased by 32-
h post treatment. Neither CAT38 nor Hb12 cells showed any
consistent changes in this phospholipid. PtdEplasm, a major
phospholipid in mitochondrial membranes [51], increased in
the presence of dexamethasone in all three cell variants,
although the increase was seen earlier in the steroid-sensi-
tive WEHI7.2 cells. AAPtdE, the precursor to PtdEplasm,
increased in all three cell variants over time independent of
drug treatment. The greatest increase was seen in the Hb12
cells.
3.6. PtdS, phosphatidylinositol (PtdI), SM
Although PtdS, PtdI and sphingomyelin (SM) are minor
membrane components, these phospholipids may be in-
volved in signaling during apoptosis [29,35,52]. PtdSnd Hb12 cells over time in the presence and absence of dexamethasone.
yl-2-acyl-phosphatidylethanolamine; PtdEplasm, phosphatidylethanolamine
r 4). (*) Denotes significantly different from the ETOH-treated sample of the
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sone treatment (Fig. 6). There was a slight increase in PtdS
by 40 h in the CAT38 cells, but not of the magnitude seen
in the WEHI7.2 cells. PtdI also significantly increased in
WEHI7.2 cells by 12 h in dexamethasone and was
significantly greater in CAT38 cells by 40 h after drug
treatment. Sphingomyelin significantly increased in
WEHI7.2 cells by 32 h and in CAT38 cells by 40 h after
dexamethasone addition.
3.7. Mitochondrial lipids
Mitochondria are critical in steroid-induced lymphocyte
apoptosis because the release of cytochrome c into the
cytosol is considered the committed step in this pathway
[53–55]. Cardiolipin content [56] and oxidation of CL
may play a role in cytochrome c release [57]. CL
concentration was significantly increased in WEHI7.2
cells 24 h after dexamethasone treatment (24-h ETOH
2.66F 0.11 vs. 24-h DEX 3.686F 0.13 nmol/mg prot)
and remained elevated after 32 h in the presence of drug.
CL in CAT38 and Hb12 cells showed no significantFig. 6. Comparison of phosphatidylserine, phosphatidylinositol and sphingomye
presence and absence of dexamethasone. Abbreviations are: PtdS, phosphatidylser
concentration + S.E. (n= 3 or 4). (*) Denotes significantly different from the ETOdexamethasone effect. Phosphatidylglycerol, the CL pre-
cursor, did not show significant alterations due to dexa-
methasone treatment. However, CAT38 and Hb12 cells
did show a significant decrease in PtdG from 12 to 40
h in culture independent of drug treatment (data not
shown).
3.8. General phospholipid parameters
In WEHI7.2 cells there was a significant increase in total
phospholipid/mg prot after dexamethasone treatment that
was not seen in the absence of steroids (Fig. 7). CAT38
cells, in the presence of dexamethasone, showed a tendency
toward higher total phospholipids by 40 h. There were also
significant differences in the PC-containing lipids (PC-L)
vs. the PE-containing lipids (PE-L). WEHI7.2 cells had a
significantly higher PC-L/PE-L ratio at 12-h ETOH than
CAT38 cells and CAT38 cells were significantly higher
than Hb12 cells. This relationship was maintained for each
time point. This ratio decreased over time in each cell variant
in the presence or absence of dexamethasone. The entire data
set including each parameter expressed as nmol/mg prot andlin concentrations in WEHI7.2, CAT38 and Hb12 cells over time in the
ine and PtdI, phosphatidylinositol. Each bar represents the mean metabolite
H-treated sample of the same cell variant at the same timepoint ( PV 0.05).
Fig. 7. Comparison of the total phospholipid concentration and the relative amounts of choline-containing to ethanolamine-containing lipids in WEHI7.2,
CAT38 and Hb12 cells over time in the presence and absence of dexamethasone. Abbreviations are: PC-L, phosphocholine-containing lipids; PE-L,
phosphoethanolamine-containing lipids. Each bar represents the mean + S.E. (n= 3 or 4). (*) Denotes significantly different from the ETOH-treated sample of
the same cell variant at the same time point ( PV 0.05).
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arizona.edu/NMRdata/Index.html.4. Discussion
4.1. LysoPtdC and apoptosis
Dexamethasone treatment causes multiple alterations in
phospholipid metabolism, several of which precede the
appearance of other markers of apoptosis. This suggests
that metabolites from these pathways may be critical during
the signaling phase of steroid-induced lymphocyte apopto-
sis. In particular, the increases seen in lysoPtdC after steroid
treatment indicate that PtdC metabolism may play a role in
this process. LysoPtdC increases are correlated with the
steroid sensitivity of the WEHI7.2 variants such that the
increase is seen earliest in the steroid-sensitive WEHI7.2
cells, is delayed in the CAT38 cells and shows no consistent
change in the steroid-resistant Hb12 cells after dexametha-
sone treatment. The increase at 12-h post-dexamethasone
treatment in the WEHI7.2 cells occurs sufficiently early to
indicate a signaling event, i.e. before the release of cyto-
chrome c, which we begin to detect 16-h post treatment
[11].
Increased lysoPtdC can cause apoptosis in some model
systems; however, the mechanism is unknown [58,59]. One
possibility is that lysoPtdC inhibits the activity of phospho-
choline cytidylyltransferase [46] resulting in apoptosis due
to a depletion of PtdC [46,60]. The increased PtdC in thedexamethasone-treated WEHI7.2 cells suggests that this is
not the mechanism in these cells. Alternatively, increased
lysoPtdC can affect membrane fluidity and permeability and
act as a detergent [22,58,61]. Although the total percentage
of lysoPtdC only reaches f 1.5%, well below the 4–5%
reportedly needed for a detergent effect [22,61], this does
not preclude a local increase above this value. LysoPtdC
also interacts readily with proteins affecting their function
[22], thus a local lysoPtdC increase may have critical effects
on membrane-bound proteins involved in signaling events
[58].
Increased lysoPtdC may be an indicator of the buildup of
other 31P NMR-invisible, cleavage products that can cause
apoptosis. Alterations in enzyme levels, i.e. an increase in
phospholipase A2 (PLA2), a decrease in lysophospholipase,
a decrease in acyltransferase or some combination, may be
responsible for the lysoPtdC accumulation. Increased PLA2
could result in increased free fatty acids (FA), arachidonic
acid (AA) or acyl coenzyme A if phospholipid remodeling
is also inhibited. Each of these compounds can induce
apoptosis [44,62–67] [63–65,67,68]. Several pieces of
evidence suggest that AA could be involved in steroid-
induced apoptosis. First, the lysoPtdC seen in these spectra
is due to a loss of the FA chain at the sn-2 position where
AA usually occurs [51]. AA is also implicated as the
causative agent in non-steroidal anti-inflammatory drug
(NSAID)-induced apoptosis in colon carcinoma cells
[43,44]. In these cells, NSAIDs work by blocking cyclo-
oxygenase-2 (COX-2) resulting in a buildup of AA and
apoptosis. Glucocorticoids are steroidal anti-inflammatory
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These data also fit with the data from Di Vito et al. [70]
where an increase in mobile lipid domains in Jurkat T-
lymphocytes during dexamethasone-induced apoptosis was
seen. These domains are rich in triglycerides and cholesterol
esters, which can act as free FA and AA carriers [71].
Another possibility is that the increase in lysoPtdC seen in
the WEHI7.2 cells is the result of an increased ROS attack on
membrane phospholipids. Data from our laboratory and
others, e.g. Refs. [12,19,72,73], suggest that in lymphocytes
increased ROS production after steroid treatment is impor-
tant in the signaling phase of apoptosis. Increased lysoPtdC
in the cells undergoing apoptosis may indicate the presence
of lipid peroxidation products, which can bind to and
damage DNA and proteins [21] and lead to apoptosis. AA
and other polyunsaturated FA, which usually are in the sn-2
position, are particularly vulnerable to ROS attack [21].
Spontaneous release of the lipid peroxide product often
leaves a short carbon chain in this position. PAF acetylhy-
drolase, a specialized PLA2 that degrades platelet-activating
factor (PAF), can remove these short chains to generate
lysoPtdC [49,74] which would appear in these spectra.
4.2. Dexamethasone and PtdC metabolism
The initial increase in PC along with the maintenance or
increase in PtdC suggests that PtdC synthesis is not
inhibited and may in fact be stimulated by glucocorticoids.
The initial PC increase is followed by a decrease at the later
time points. This is in agreement with the dexamethasone-
dependent decrease in PME seen by Adebodun and Post
[25]. The PC decrease is accompanied by a decrease in Gro-
3-P suggesting that the precursors are being consumed. The
lack of quantifiable choline and CDP-choline in these
samples suggests that dexamethasone does not block cho-
line kinase or phosphocholine DAG transferase.
Hb12 cells show little accumulation of lysoPtdC in the
presence of dexamethasone and the greatest increase in
GPC, suggesting these cells have an increased ability to
degrade phospholipids to PDE. This is supported by the
much higher GPE and GPG in these cells even in the
absence of dexamethasone treatment. An increased ability
to degrade phospholipids may be one way that Bcl-2
provides protection against ROS-induced apoptosis. There
are several reports where baseline ROS are higher or an
ROS increase is seen after oxidant treatment in bcl-2 trans-
fectants, yet no alteration in lipid peroxidation can be
detected [13,14,75,76]. An increased ability to remove
damaged lipids could help to explain these data. There is
some recent evidence that Bcl-2 family members affect
membrane lipid metabolism [77].
4.3. Phospholipids as apoptotic signals
Our data do not support a role for the activation of
sphingomyelinase in steroid-induced apoptosis in WEHI7.2cells. Increased sphingomyelinase activity and production of
ceramide has been implicated in steroid-induced lympho-
cyte apoptosis in the work by Cifone et al. [29]. Dexameth-
asone treatment causes an increase in PC content which
could reflect increased sphingomyelinase activity; however,
in WEHI7.2 and CAT38 cells dexamethasone causes an
increase in SM rather than the decrease that would be
expected if sphingomyelinase was activated [43]. This
suggests that sphingomyelinase is not involved, but it is
also possible that SM synthesis outstrips demand or activa-
tion occurs prior to our measurements.
4.4. Phospholipids and tumorigenesis
Recognition of apoptotic cells in vivo seems to require
the externalization of PtdS [35]. In severe-combined-immu-
nodeficient mice, WEHI7.2 cells are least tumorigenic,
CAT38 cells are intermediate and Hb12 cells are the most
tumorigenetic [10,11]. This difference can be traced to a
difference in the rates of spontaneous apoptosis in these
tumors. Apoptotic cells from WEHI7.2 cell tumors are
readily phagocytized. The increased amount of PtdS seen
with dexamethasone treatment in the WEHI7.2 cells and
mouse thymocytes [78] could serve to increase recognition
of apoptotic cells. The increased AAPtdC and lysoPtdC
seen after dexamethasone treatment may also play a role in
phagocytosis because one species of the AAPtdC family is
PAF; both PAF and lysoPtdC have been shown to stimulate
macrophages [79]. In tumors from CAT38 cells, dead cells
were not as readily phagocytized as in WEHI7.2 cell
tumors. In CAT38 cells PtdS content does not increase with
dexamethasone treatment and PtdS externalization is not
equivalent to that in WEHI7.2 cells. For example, after 40
h in dexamethasone, the cytochrome c release in CAT38
cells is comparable to that in WEHI7.2 cells at 32 h [11], yet
the PtdS externalization is much less. We also do not see the
AAPtdC increase in these cells. These data suggest that
resistance to apoptosis may be accompanied by decreased
recognition and phagocytosis of dead cells.
A decreased PC/APDE ratio is correlated with increased
resistance to dexamethasone and increased tumorigenicity in
these cells. This is primarily due to slightly increased PDE
in CAT38 cells and greatly increased PDE values in Hb12
cells. These data suggest that the ability to degrade phos-
pholipids to PDE may be important for both resistance to
dexamethasone and tumorigenicity. The appearance of in-
creased lysoPtdC prior to the release of cytochrome c into
the cytosol suggests that perturbations in PtdC metabolism
may be involved in apoptotic signaling. Altered phospho-
lipid metabolism in the resistant variants may either prevent
the appearance of these signals or remove them before there
is a downstream effect. The variants analyzed in this study
provide a good model to further explore these possibilities.
Although it is beyond the scope of this manuscript to
thoroughly discuss the phospholipid alterations in light of
cell cycle alterations and other phenotypic changes in these
M.E. Tome et al. / Biochimica et Biophysica Acta 1642 (2003) 149–162160cells, these data indicate that overexpression of Bcl-2 or
catalase and cell cycle arrest have multiple affects on
phospholipid metabolism.Acknowledgements
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